WallStreetZenWallStreetZen

NYSEMKT: NBY
Novabay Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NBY stock forecasts and price targets.

Forecast return on equity

Is NBY forecast to generate an efficient return?

Company
-4,360.95%
Industry
40.35%
Market
344.29%
NBY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NBY forecast to generate an efficient return on assets?

Company
-1,386.95%
Industry
18.25%
NBY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NBY earnings per share forecast

What is NBY's earnings per share in the next 1 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.38-116.47%

NBY revenue forecast

What is NBY's revenue in the next 1 years based on estimates from 2 analysts?

Avg 1 year Forecast
$16.0M+465.51%

NBY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NBY$1.86N/AN/A
MDWD$18.13$36.00+98.57%Buy
CNTX$2.61$6.50+149.04%Strong Buy
SLN$4.82$55.00+1,041.08%Strong Buy
HRTX$1.32$4.50+240.91%Buy
View Top Biotech Stocks

Novabay Pharmaceuticals Stock Forecast FAQ

What is NBY's earnings growth forecast for 2026-2026?

(NYSEMKT: NBY) Novabay Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Novabay Pharmaceuticals's earnings in 2026 is $3,243,000.

In 2026, NBY is forecast to generate -$48,362,925 in earnings, with the lowest earnings forecast at -$46,926,403 and the highest earnings forecast at -$50,278,289.

If you're new to stock investing, here's how to buy Novabay Pharmaceuticals stock.

What is NBY's revenue growth forecast for 2026-2026?

(NYSEMKT: NBY) Novabay Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Novabay Pharmaceuticals's revenue in 2026 is $2,830,000.

In 2026, NBY is forecast to generate $2,016,676,027 in revenue, with the lowest revenue forecast at $1,956,820,921 and the highest revenue forecast at $2,096,566,842.

What is NBY's forecast return on assets (ROA) for 2026-2026?

(NYSEMKT: NBY) forecast ROA is -1,386.95%, which is lower than the forecast US Biotechnology industry average of 18.25%.

What is NBY's Earnings Per Share (EPS) forecast for 2026-2026?

(NYSEMKT: NBY) Novabay Pharmaceuticals's current Earnings Per Share (EPS) is $2.33. In 2026, NBY's EPS is forecast to hit -$0.38 (min: -$0.37, max: -$0.40).

What is NBY's forecast return on equity (ROE) for 2026-2026?

(NYSEMKT: NBY) forecast ROE is -4,360.95%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.